Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques

Clinical Immunology

Volumn 155, Issue 1, 2014, Pages 91-107

  Valentin, Antonio ^a   McKinnon, Katherine ^b   Li, Jinyao ^a   Rosati, Margherita ^a   Kulkarni, Viraj ^a   Pilkington, Guy R ^a   Bear, Jenifer ^a   Alicea, Candido ^a   Vargas Inchaustegui, Diego A ^b   Jean Patterson, L ^b   Pegu, Poonam ^b   Liyanage, Namal P M ^b   Gordon, Shari N ^b   Vaccari, Monica ^b   Wang, Yichuan ^b   Hogg, Alison E ^b   Frey, Blake ^b   Sui, Yongjun ^b   Reed, Steven G ^c   Sardesai, Niranjan Y ^d   Berzofsky, Jay A ^b   Franchini, Genoveffa ^b   Robert Guroff, Marjorie ^b   Felber, Barbara K ^a   Pavlakis, George N ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Infectious Diseases Research Institute   (United States)

^d Inovio Pharmaceuticals Inc   (United States)

Author keywords

Cellular immune response; DNA; Pox virus ALVAC MVA; Prime boost vaccination; Protein

Indexed keywords

DNA; DNA VACCINE; MODIFIED VACCINIA ANKARA VACCINE; PLASMID DNA; RECOMBINANT CANARY POX VIRUS ALVAC VACCINE; REPLICATION COMPETENT ADENOVIRUS TYPE 5 HOST RANGE MUTANT REPAD VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL TISSUE; ARTICLE; AUTOPSY; CANARYPOX VIRUS; CELLULAR IMMUNITY; COMPARATIVE STUDY; HOST RANGE; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; LIVER; LYMPH NODE; NONHUMAN; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; T LYMPHOCYTE; TISSUE DISTRIBUTION; VAGINA; VIRUS REPLICATION; ANIMAL; CD8+ T LYMPHOCYTE; CELL CULTURE; FEMALE; IMMUNOLOGY;

ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; IMMUNITY, CELLULAR; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL VACCINES;

EID: 84907539519     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.09.005     Document Type: Article

References (77)

1. Berman P.W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses 1998, 14(Suppl. 3):S277-S289.
2. Francis D.P., Gregory T., McElrath M.J., Belshe R.B., Gorse G.J., Migasena S., Kitayaporn D., Pitisuttitham P., Matthews T., Schwartz D.H., Berman P.W. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res. Hum. Retroviruses 1998, 14(Suppl. 3):S325-S331.
3. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K., G.Bangkok Vaccine Evaluation Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
4. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., H.I.V.V.S.G.rgp Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191:654-665.
5. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
6. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., Heath L., Magaret C.A., Bose M., Bradfield A., O'Sullivan A., Crossler J., Jones T., Nau M., Wong K., Zhao H., Raugi D.N., Sorensen S., Stoddard J.N., Maust B.S., Deng W., Hural J., Dubey S., Michael N.L., Shiver J., Corey L., Li F., Self S.G., Kim J., Buchbinder S., Casimiro D.R., Robertson M.N., Duerr A., McElrath M.J., McCutchan F.E., Mullins J.I. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 2011, 17:366-371.
7. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
8. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., Koblin B.A., Buchbinder S.P., Keefer M.C., Tomaras G.D., Frahm N., Hural J., Anude C., Graham B.S., Enama M.E., Adams E., DeJesus E., Novak R.M., Frank I., Bentley C., Ramirez S., Fu R., Koup R.A., Mascola J.R., Nabel G.J., Montefiori D.C., Kublin J., McElrath M.J., Corey L., Gilbert P.B., Team H.S. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013, 369:2083-2092.
9. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
10. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., Ahmed H., Juraska M., Chen L., Konopa P., Nariya S., Stoddard J.N., Wong K., Zhao H., Deng W., Maust B.S., Bose M., Howell S., Bates A., Lazzaro M., O'Sullivan A., Lei E., Bradfield A., Ibitamuno G., Assawadarachai V., O'Connell R.J., deSouza M.S., Nitayaphan S., Rerks-Ngarm S., Robb M.L., McLellan J.S., Georgiev I., Kwong P.D., Carlson J.M., Michael N.L., Schief W.R., Gilbert P.B., Mullins J.I., Kim J.H. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
11. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
12. Gottardo R., Bailer R.T., Korber B.T., Gnanakaran S., Phillips J., Shen X., Tomaras G.D., Turk E., Imholte G., Eckler L., Wenschuh H., Zerweck J., Greene K., Gao H., Berman P.W., Francis D., Sinangil F., Lee C., Nitayaphan S., Rerks-Ngarm S., Kaewkungwal J., Pitisuttithum P., Tartaglia J., Robb M.L., Michael N.L., Kim J.H., Zolla-Pazner S., Haynes B.F., Mascola J.R., Self S., Gilbert P., Montefiori D.C. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013, 8:e75665.
13. Zolla-Pazner S., deCamp A.C., Cardozo T., Karasavvas N., Gottardo R., Williams C., Morris D.E., Tomaras G., Rao M., Billings E., Berman P., Shen X., Andrews C., O'Connell R.J., Ngauy V., Nitayaphan S., de Souza M., Korber B., Koup R., Bailer R.T., Mascola J.R., Pinter A., Montefiori D., Haynes B.F., Robb M.L., Rerks-Ngarm S., Michael N.L., Gilbert P.B., Kim J.H. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013, 8:e53629.
14. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R.T., Koup R.A., Madnote S., Arworn D., Shen X., Tomaras G.D., Currier J.R., Jiang M., Magaret C., Andrews C., Gottardo R., Gilbert P., Cardozo T.J., Rerks-Ngarm S., Nitayaphan S., Pitisuttithum P., Kaewkungwal J., Paris R., Greene K., Gao H., Gurunathan S., Tartaglia J., Sinangil F., Korber B.T., Montefiori D.C., Mascola J.R., Robb M.L., Haynes B.F., Ngauy V., Michael N.L., Kim J.H., de Souza M.S. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012, 28:1444-1457.
15. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., Tryniszewska E., Lewis M.G., VanCott T.C., Hirsch V., Woodward R., Gibson A., Grace M., Dobratz E., Markham P.D., Hel Z., Nacsa J., Klein M., Tartaglia J., Franchini G. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 2002, 76:292-302.
16. Pal R., Venzon D., Santra S., Kalyanaraman V.S., Montefiori D.C., Hocker L., Hudacik L., Rose N., Nacsa J., Edghill-Smith Y., Moniuszko M., Hel Z., Belyakov I.M., Berzofsky J.A., Parks R.W., Markham P.D., Letvin N.L., Tartaglia J., Franchini G. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J. Virol. 2006, 80:3732-3742.
17. Hel Z., Nacsa J., Tsai W.P., Thornton A., Giuliani L., Tartaglia J., Franchini G. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 2002, 304:125-134.
18. Pegu P., Vaccari M., Gordon S., Keele B.F., Doster M., Guan Y., Ferrari G., Pal R., Ferrari M.G., Whitney S., Hudacik L., Billings E., Rao M., Montefiori D., Tomaras G., Alam S.M., Fenizia C., Lifson J.D., Stablein D., Tartaglia J., Michael N., Kim J., Venzon D., Franchini G. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 2013, 87:1708-1719.
19. Vaccari M., Keele B.F., Bosinger S.E., Doster M.N., Ma Z.M., Pollara J., Hryniewicz A., Ferrari G., Guan Y., Forthal D.N., Venzon D., Fenizia C., Morgan T., Montefiori D., Lifson J.D., Miller C.J., Silvestri G., Rosati M., Felber B.K., Pavlakis G.N., Tartaglia J., Franchini G. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J. Virol. 2013, 87:3538-3548.
20. Patterson L.J., Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin. Biol. Ther. 2008, 8:1347-1363.
21. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M., Markham P.D., Zolla-Pazner S., Steimer K., Wade M., Reitz M.S., Arthur L.O., Mizutani S., Davis A., Hung P.P., Gallo R.C., Eichberg J., Robert-Guroff M. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 1997, 3:651-658.
22. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., Kalyanaraman V.S., Pal R., Lee E.M., Zhao J., Cristillo A., Robert-Guroff M. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353:83-98.
23. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Korioth-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., Ensoli B., Robert-Guroff M. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2007, 81:3414-3427.
24. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., Mortier D., Lian Y., Oostermeijer H., Fagrouch Z., Dubbes R., van der Maas M., Mooij P., Koopman G., Verschoor E., Langedijk J.P., Zhao J., Brocca-Cofano E., Robert-Guroff M., Srivastava I., Barnett S., Heeney J.L. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008, 382:217-225.
25. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., Zhao J., DiPasquale J., Fenizia C., Lee E.M., Kalisz I., Kalyanaraman V.S., Pal R., Montefiori D., Keele B.F., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 2012, 86:4644-4657.
26. Jalah R., Patel V., Kulkarni V., Rosati M., Alicea C., Ganneru B., von Gegerfelt A., Huang W., Guan Y., Broderick K.E., Sardesai N.Y., Labranche C., Montefiori D.C., Pavlakis G.N., Felber B.K. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum. Vaccin. Immunother. 2012, 8:1620-1629.
27. Rosati M., Bergamaschi C., Valentin A., Kulkarni V., Jalah R., Patel V., von Gegerfelt A.S., Montefiori D.C., Venzon D., Khan A.S., Draghia-Akli R., Van Rompay K.K.A., Felber B.K., Pavlakis G.N. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc. Natl. Acad. Sci. U. S. A. 2009, 06:15831-15836.
28. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., Alicea C., Weiss D., Treece J., Pal R., Markham P.D., Marques E.T., August J.T., Khan A., Draghia-Akli R., Felber B.K., Pavlakis G.N. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26:5223-5229.
29. Kulkarni V., Jalah R., Ganneru B., Bergamaschi C., Alicea C., von Gegerfelt A., Patel V., Zhang G.M., Chowdhury B., Broderick K.E., Sardesai N.Y., Valentin A., Rosati M., Felber B.K., Pavlakis G.N. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2011, 29:6742-6754.
30. Kulkarni V., Valentin A., Rosati M., Alicea C., Singh A.K., Jalah R., Broderick K.E., Sardesai N.Y., Le Gall S., Mothe B., Brander C., Rolland M., Mullins J.I., Pavlakis G.N., Felber B.K. Altered immunodominance hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS One 2014, 9:e86254.
31. Li J., Valentin A., Kulkarni V., Rosati M., Beach R.K., Alicea C., Bear J., Hannaman D., Reed S.G., Felber B.K., Pavlakis G.N. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013, 31:3747-3755.
32. Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., von Gegerfelt A., Huang W., Guan Y., Keele B., Bess J., Piatak M., Lifson J.D., Willliams W.T., Shen X., Tomaras G.D., Amara R.R., Robinson H.L., Johnson W., Broderick K.E., Sardesai N.Y., Venzon D., Hirsch V.M., Felber B.K., Pavlakis G.N. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous SIV challenge. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2975-2980.
33. Patel V., Valentin A., Kulkarni V., Rosati M., Bergamaschi C., Jalah R., Alicea C., Minang J.T., Trivett M.T., Ohlen C., Zhao J., Robert-Guroff M., Khan A.S., Draghia-Akli R., Felber B.K., Pavlakis G.N. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010, 28:4827-4836.
34. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., Markham P.D., Pal R., Clements J.D., Lewis M.G., Strober W., Franchini G., Berzofsky J.A. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
35. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Sette A., Altman J., Woodward R., Markham P.D., Clements J.D., Franchini G., Strober W., Berzofsky J.A. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 2001, 7:1320-1326.
36. Sui Y., Zhu Q., Gagnon S., Dzutsev A., Terabe M., Vaccari M., Venzon D., Klinman D., Strober W., Kelsall B., Franchini G., Belyakov I.M., Berzofsky J.A. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9843-9848.
37. Sui Y., Gagnon S., Dzutsev A., Zhu Q., Yu H., Hogg A., Wang Y., Xia Z., Belyakov I.M., Venzon D., Klinman D., Strober W., Kelsall B., Franchini G., Berzofsky J.A. TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4(+) memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine 2011, 30:59-68.
38. Vargas-Inchaustegui D.A., Tuero I., Mohanram V., Musich T., Pegu P., Valentin A., Sui Y., Rosati M., Bear J., Kulkarni V., Alicea C., Pilkington G.R., Venzon V., Liyanage N.P., T.D.T., Gordon S.N., Wang Y., Hogg A.E., Frey B., Patterson L.J., DiPasquale J., Montefiori D.C., Sardesai N.Y., Reed S.G., Tartaglia J., Berzofsky J.A., Franchini G., Felber B.K., Pavlakis G.N., Robert-Guroff M. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggest novel combinatorial approaches for enhancing responses. Clin. Immunol. 2014, 153:308-322.
39. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G.H., Nickle D., Rousseau C., Coovadia H., Mullins J.I., Heckerman D., Walker B.D., Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007, 13:46-53.
40. Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H., Payne R., Reddy S., Bishop K., Moodley E., Nair K., van der Stok M., McCarthy N., Rousseau C.M., Addo M., Mullins J.I., Brander C., Kiepiela P., Walker B.D., Goulder P.J. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 2007, 81:3667-3672.
41. Schneidewind A., Brockman M.A., Yang R., Adam R.I., Li B., Le Gall S., Rinaldo C.R., Craggs S.L., Allgaier R.L., Power K.A., Kuntzen T., Tung C.S., LaBute M.X., Mueller S.M., Harrer T., McMichael A.J., Goulder P.J., Aiken C., Brander C., Kelleher A.D., Allen T.M. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 2007, 81:12382-12393.
42. Ngumbela K.C., Day C.L., Mncube Z., Nair K., Ramduth D., Thobakgale C., Moodley E., Reddy S., de Pierres C., Mkhwanazi N., Bishop K., van der Stok M., Ismail N., Honeyborne I., Crawford H., Kavanagh D.G., Rousseau C., Nickle D., Mullins J., Heckerman D., Korber B., Coovadia H., Kiepiela P., Goulder P.J., Walker B.D. Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res. Hum. Retroviruses 2008, 24:72-82.
43. Rolland M., Heckerman D., Deng W., Rousseau C.M., Coovadia H., Bishop K., Goulder P.J., Walker B.D., Brander C., Mullins J.I. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008, 3:e1424.
44. Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., Colvin M., Zijenah L., Katzenstein D., Musonda R., Allen S., Kumwenda N., Taha T., Gray G., McIntyre J., Karim S.A., Sheppard H.W., Gray C.M. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J. Virol. 2004, 78:3233-3243.
45. Mothe B., Ibarrondo J., Llano A., Brander C. Virological, immune and host genetics markers in the control of HIV infection. Dis. Markers 2009, 27:105-120.
46. Zuniga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., Sanchez H., Frahm N., Linde C.H., Hewitt H.S., Hildebrand W., Altfeld M., Allen T.M., Walker B.D., Korber B.T., Leitner T., Sanchez J., Brander C. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 2006, 80:3122-3125.
47. Mothe B., Llano A., Ibarrondo J., Zamarreno J., Schiaulini M., Miranda C., Ruiz-Riol M., Berger C.T., Herrero M.J., Palou E., Plana M., Rolland M., Khatri A., Heckerman D., Pereyra F., Walker B.D., Weiner D., Paredes R., Clotet B., Felber B.K., Pavlakis G.N., Mullins J.I., Brander C. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 2012, 7:e29717.
48. Mothe B., Llano A., Ibarrondo J., Daniels M., Miranda C., Zamarreno J., Bach V., Zuniga R., Perez-Alvarez S., Berger C.T., Puertas M.C., Martinez-Picado J., Rolland M., Farfan M., Szinger J.J., Hildebrand W.H., Yang O.O., Sanchez-Merino V., Brumme C.J., Brumme Z.L., Heckerman D., Allen T.M., Mullins J.I., Gomez G., Goulder P.J., Walker B.D., Gatell J.M., Clotet B., Korber B.T., Sanchez J., Brander C. Definition of the viral targets of protective HIV-1-specific T cell responses. J. Transl. Med. 2011, 9:208.
49. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., Iampietro M.J., SanMiguel A., Seaman M.S., Ferrari G., Forthal D.N., Ourmanov I., Hirsch V.M., Carville A., Mansfield K.G., Stablein D., Pau M.G., Schuitemaker H., Sadoff J.C., Billings E.A., Rao M., Robb M.L., Kim J.H., Marovich M.A., Goudsmit J., Michael N.L. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
50. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., Landucci G., Forthal D.N., Montefiori D.C., Carville A., Mansfield K.G., Havenga M.J., Pau M.G., Goudsmit J., Barouch D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
51. Manrique M., Kozlowski P.A., Cobo-Molinos A., Wang S.W., Wilson R.L., Martinez-Viedma Mdel P., Montefiori D.C., Carville A., Aldovini A. Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J. Virol. 2014, 88:212-224.
52. Manrique M., Kozlowski P.A., Cobo-Molinos A., Wang S.W., Wilson R.L., Montefiori D.C., Mansfield K.G., Carville A., Aldovini A. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 2011, 186:3581-3593.
53. Pahar B., Gray W.L., Phelps K., Didier E.S., deHaro E., Marx P.A., Traina-Dorge V.L. Increased cellular immune responses and CD4+ T-cell proliferation correlate with reduced plasma viral load in SIV challenged recombinant simian varicella virus-simian immunodeficiency virus (rSVV-SIV) vaccinated rhesus macaques. Virology 2012, 9:160.
54. Schultheiss T., Schulte R., Sauermann U., Ibing W., Stahl-Hennig C. Strong mucosal immune responses in SIV infected macaques contribute to viral control and preserved CD4+ T-cell levels in blood and mucosal tissues. Retrovirology 2011, 8:24.
55. Kawada M., Tsukamoto T., Yamamoto H., Takeda A., Igarashi H., Watkins D.I., Matano T. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J. Virol. 2007, 81:5202-5211.
56. Mattapallil J.J., Hill B., Douek D.C., Roederer M. Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J. Med. Primatol. 2006, 35:217-224.
57. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., Gonzalez E.J., Yant L.J., Maness N.J., May G.E., Soma T., Reynolds M.R., Rakasz E., Rudersdorf R., McDermott A.B., O'Connor D.H., Friedrich T.C., Allison D.B., Patki A., Picker L.J., Burton D.R., Lin J., Huang L., Patel D., Heindecker G., Fan J., Citron M., Horton M., Wang F., Liang X., Shiver J.W., Casimiro D.R., Watkins D.I. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 2006, 80:5875-5885.
58. Yamamoto T., Johnson M.J., Price D.A., Wolinsky D.I., Almeida J.R., Petrovas C., Nason M., Yeh W.W., Shen L., Roederer M., Rao S.S., McDermott A.B., Lefebvre F., Nabel G.J., Haddad E.K., Letvin N.L., Douek D.C., Koup R.A. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J. Virol. 2012, 86:5877-5884.
59. Boyer J.D., Maciag P.C., Parkinson R., Wu L., Lewis M.G., Weiner D.B., Paterson Y. Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine 2006, 24:4498-4502.
60. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., Felber B.K., Tartaglia J., Pavlakis G.N., Franchini G. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 2002, 169:4778-4787.
61. Vaccari M., Mattapallil J., Song K., Tsai W.P., Hryniewicz A., Venzon D., Zanetti M., Reimann K.A., Roederer M., Franchini G. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J. Virol. 2008, 82:9629-9638.
62. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., Venzon D., Montefiori D.C., Markham P., Felber B.K., Pavlakis G.N. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J. Virol. 2005, 79:8480-8492.
63. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., Kalyanaraman V.S., Markham P.D., Robey F.A., Robert-Guroff M. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 2004, 78:2212-2221.
64. Patterson L.J., Daltabuit-Test M., Xiao P., Zhao J., Hu W., Wille-Reece U., Brocca-Cofano E., Kalyanaraman V.S., Kalisz I., Whitney S., Lee E.M., Pal R., Montefiori D.C., Dandekar S., Seder R., Roederer M., Wiseman R.W., Hirsch V., Robert-Guroff M. Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 2011, 411:87-102.
65. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., Oswald K., Shoemaker R., Li Y., Lewis M.S., Gilliam A.N., Xu G., Whizin N., Burwitz B.J., Planer S.L., Turner J.M., Legasse A.W., Axthelm M.K., Nelson J.A., Fruh K., Sacha J.B., Estes J.D., Keele B.F., Edlefsen P.T., Lifson J.D., Picker L.J. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
66. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
67. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis M.A., Piatak M., Lifson J.D., Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
68. Wilson N.A., Keele B.F., Reed J.S., Piaskowski S.M., MacNair C.E., Bett A.J., Liang X., Wang F., Thoryk E., Heidecker G.J., Citron M.P., Huang L., Lin J., Vitelli S., Ahn C.D., Kaizu M., Maness N.J., Reynolds M.R., Friedrich T.C., Loffredo J.T., Rakasz E.G., Erickson S., Allison D.B., Piatak M., Lifson J.D., Shiver J.W., Casimiro D.R., Shaw G.M., Hahn B.H., Watkins D.I. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 2009, 83:6508-6521.
69. Mudd P.A., Martins M.A., Ericsen A.J., Tully D.C., Power K.A., Bean A.T., Piaskowski S.M., Duan L., Seese A., Gladden A.D., Weisgrau K.L., Furlott J.R., Kim Y.I., Veloso de Santana M.G., Rakasz E., Capuano S., Wilson N.A., Bonaldo M.C., Galler R., Allison D.B., Piatak M., Haase A.T., Lifson J.D., Allen T.M., Watkins D.I. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012, 491:129-133.
70. Martins M.A., Wilson N.A., Piaskowski S.M., Weisgrau K.L., Furlott J.R., Bonaldo M.C., Veloso de Santana M.G., Rudersdorf R.A., Rakasz E.G., Keating K.D., Chiuchiolo M.J., Piatak M., Allison D.B., Parks C.L., Galler R., Lifson J.D., Watkins D.I. Vaccination with gene fragments of gag, vif, and nef affords partial control of viral replication after mucosal challenge with SIVmac239. J. Virol. 2014, 88:7493-7516.
71. Giraldo-Vela J.P., Bean A.T., Rudersdorf R., Wallace L.T., Loffredo J.T., Erickson P., Wilson N.A., Watkins D.I. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics 2010, 62:701-707.
72. Kawada M., Tsukamoto T., Yamamoto H., Iwamoto N., Kurihara K., Takeda A., Moriya C., Takeuchi H., Akari H., Matano T. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J. Virol. 2008, 82:10199-10206.
73. Jalah R., Kulkarni V., Patel V., Rosati M., Alicea C., Bear J., Yu L., Guan Y., Shen X., Tomaras G.D., LaBranche C., Montefiori D.C., Bess J., Lifson J.D., Reed S., Sardesai N.Y., Venzon D., Valentin A., Pavlakis G.N., Felber B.K. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in rhesus macaques. PLoS One 2014, 9:e91550.
74. Genesca M., Skinner P.J., Bost K.M., Lu D., Wang Y., Rourke T.L., Haase A.T., McChesney M.B., Miller C.J. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 2008, 1:219-228.
75. Genesca M., McChesney M.B., Miller C.J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J. Intern. Med. 2009, 265:67-77.
76. Manrique M., Kozlowski P.A., Cobo-Molinos A., Wang S.W., Wilson R.L., Montefiori D.C., Carville A., Aldovini A. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. J. Virol. 2013, 87:4738-4750.
77. Strbo N., Vaccari M., Pahwa S., Kolber M.A., Fisher E., Gonzalez L., Doster M.N., Hryniewicz A., Felber B.K., Pavlakis G.N., Franchini G., Podack E.R. Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine 2011, 29:2619-2625.